SCHEDULE: Octagon Capital Advisors Discloses 3.6% Stake in Dianthus Therapeutics

Octagon Capital Advisors LP and affiliated entities have reported beneficial ownership of 3.6% of Dianthus Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Octagon Capital Advisors LP, along with Octagon Investments Master Fund LP, Octagon Biotech Opportunities Fund I LP, and Ting Jia, have jointly filed a Schedule 13G, indicating their beneficial ownership of Dianthus Therapeutics, Inc. common stock.
• As of March 31, 2026, the Reporting Persons collectively beneficially own 1,946,667 shares of common stock, representing 3.6% of the class.
• Octagon Capital Advisors LP serves as the investment manager for the Master Fund and Biotech Fund I, and Ting Jia is the principal beneficial owner and managing member of Octagon Capital Advisors LP.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, indicating a standard investment disclosure without immediate positive or negative implications for the company's stock price.

Positives

• Significant investment by Octagon Capital Advisors LP and its affiliates, suggesting confidence in Dianthus Therapeutics' potential.
• The filing indicates the shares are held in the ordinary course of business, implying a standard investment strategy rather than a hostile takeover attempt.

Negatives

• The reporting persons collectively hold less than 5% of the outstanding shares, which may limit their influence on corporate decisions.
• The filing does not provide specific details on the acquisition cost or strategy behind the investment.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company's operations.
• Potential for future changes in beneficial ownership, which could impact share price and corporate control.

Future Outlook

The filing does not contain forward-looking statements or specific guidance regarding future performance or intentions beyond the current investment holding.

Management Comments

• "By virtue of these relationships each of Octagon and Dr. Jia may be deemed to beneficially own the Issuer's Common Shares directly owned by the Master Fund and by the Biotech Fund I."
• "The Master Fund holds the Common Shares for the benefit of its investors. The Biotech Fund I holds the Common Shares for the benefit of its investors."
• "The Master Fund, the Biotech Fund I and Octagon, for the benefit of its investors, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares."
• "I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect..."

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Octagon Capital Advisors LP and its affiliates signifies a notable investment in Dianthus Therapeutics, Inc. Such filings often precede or coincide with shifts in investor sentiment or strategic corporate actions within the biotechnology sector, where significant ownership stakes can influence research and development trajectories or potential M&A activities.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an investment firm may influence investor perception and potentially trading activity.
• Management: The filing confirms an institutional investor's interest, which could lead to engagement on corporate strategy or governance.
• Investment Community: This filing provides transparency on ownership, aiding analysts and investors in understanding the shareholder base.

Next Steps

• Monitoring of future filings by Octagon Capital Advisors LP and its affiliates for any changes in beneficial ownership.
• Observing Dianthus Therapeutics, Inc.'s strategic developments and financial performance to assess the impact of this investment.

Key Dates

Keywords

Dianthus Therapeutics, Schedule 13G, Octagon Capital Advisors LP, Beneficial Ownership, Common Stock, Investment Management, SEC Filing, Ting Jia